Leaflet IPERTROFAN 40 150000ui (40mg) gastro-resistant film-coated tablets


Indicated for: benign prostatic hyperplasia

Route of administration: oral

Substance: mepartricin (polyene antibiotic)

ATC: G04CX03 (Genito urinary system and sex hormones | Drugs used in benign prostatic hypertrophy | Other drugs used in benign prostatic hypertrophy)

Mepartricin is a medication primarily used for the treatment of benign prostatic hyperplasia and certain inflammatory conditions of the urinary tract. It works by reducing inflammation and improving urinary flow.

The drug has anti-inflammatory and anti-estrogenic properties, making it useful in alleviating symptoms associated with prostate enlargement, such as difficulty urinating or the sensation of incomplete bladder emptying.

Mepartricin is administered orally, usually in capsule form, and the duration of treatment depends on the severity of the condition. It is important to follow the doctor's instructions to achieve the best results.

Adverse effects are rare but may include gastrointestinal disturbances or allergic reactions. Patients with hypersensitivity to this medication should avoid its use.

General data about IPERTROFAN 40 150000ui (40mg)

  • Substance: mepartricin
  • Date of last drug list: 01-07-2015
  • Commercial code: W04114002
  • Concentration: 150000ui (40mg)
  • Pharmaceutical form: gastro-resistant film-coated tablets
  • Quantity: 20
  • Product type: original
  • Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.

Marketing authorisation

  • Manufacturer: DOPPEL FARMACEUTICI SRL - ITALIA
  • Holder: S.P.A. SOCIETA PRODOTTI ANTIBIOTICI SPA - ITALIA
  • Number: 11913/2019/01
  • Shelf life: 30 months